Clinical trials: Glucose Tolerance
Diabetes Mellitus, Type 1
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the…
- Trial name
- TN07 (NCT00419562)
- Testing
- Oral Insulin
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 560 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, Impaired Glucose Tolerance
Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
- Conditions
- Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
- Trial name
- NCT00413335
- Testing
- Rosiglitazone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Pre Diabetes
Diabetes Prevention Program in Youth
The purpose of this study is to test the effectiveness of an out-of-school diabetes prevention program for youth (ages 7-15) with a family history of pre-diabetes or type 2 diabetes.
- Trial name
- NCT03042936
- Testing
- Insulin Superheroes Club Curriculum
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prediabetes, Type 1 Diabetes
Diabetes Prevention - Immune Tolerance
A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in children with multiple islet cell autoantibodies Eligible children are 4 years or…
- Trial name
- DIAPREV-IT (NCT01122446)
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Lund University
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Impaired Glucose Tolerance
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
The purpose of this study is to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical…
- Trial name
- NCT01993927
- Testing
- Voglibose
- Where
- Japan
- Volunteers
- 742 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 [Ala-Ala],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection.
- Trial name
- AbATE (NCT00129259)
- Testing
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypertriglyceridemia, Hyperglycemia
Intravenous Fat Emulsions and Premature Infants
The purpose of this study is to study the tolerances of Extremely Low Birthweight Infants who are born at less than 750 grams who are started at a higher infusion rate of intravenous lipid emulsions (2 gm/kg/day).
- Trial name
- NCT01096446
- Testing
- Intravenous Fat Emulsions
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OSF Healthcare System
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cystic Fibrosis, Prediabetes
Prevention of Cystic Fibrosis Diabetes
Acute systemic hyperglycemia causes oxidative stress and a pro-inflammatory response. The pro-inflammatory cytokines induced by hyperglycemia are toxic to islet insulin producing cells, and thus worsen glucose intolerance.
- Trial name
- Prevent (NCT00967798)
- Testing
- Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Pediatric Obesity, Insulin Resistance
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
The main purpose of this study is to determine whether treatment with acarbose attenuates post-prandial glycemic excursions in non-diabetic/pre-diabetic obese children as determined by continuous glucose monitoring systems…
- Conditions
- Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
- Trial name
- NCT00846521
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Obesity, Morbid
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy.
- Trial name
- NCT00886626
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 1, Prediabetic State
Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in…
- Trial name
- DiAPREV-IT2 (NCT02387164)
- Testing
- Alum-GAD, Vitamin D3
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Lund University
Cystic Fibrosis
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function…
- Trial name
- NCT04599465
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 41 sites in Australia, Belgium and 5 more
- Volunteers
- 69 people
- Sponsor
- Vertex Pharmaceuticals Incorporated